PCSK9 and ischemic stroke: Robust evidence from clinical trials suggests that a range of low-density lipoprotein cholesterol (LDL-C)-lowering treatments, such as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, statins, and ezetimibe, has shown promising efficacy in decreasing the risk of ischemic stroke [10, 11].